Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Required: IGHV mutation status

testing for prognostic factors according to the CLL-IPI (including IGVH mutation status); if results for any of the prognostic factors included in the CLL-IPI are unknown including IGVH mutation status results not being available due to a failed laboratory assay, the patient is not eligible

Required: CCND1 wild-type

mantle cell lymphoma must be excluded by demonstrating a negative fluorescence in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1)

Cannot have received: chemotherapy

Exception: nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate or EGCG, found in green tea or other herbal treatments or supplemental vitamins) and prior corticosteroid therapy for an indication other than CLL/SLL will not be considered 'prior treatment'

Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL or SLL will be considered prior therapy

Cannot have received: monoclonal antibody

Exception: nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate or EGCG, found in green tea or other herbal treatments or supplemental vitamins) and prior corticosteroid therapy for an indication other than CLL/SLL will not be considered 'prior treatment'

Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL or SLL will be considered prior therapy

Cannot have received: BCR inhibitor (ibrutinib)

Prior exposure to ibrutinib or to a BCR inhibitor (e.g. Btk or PI3 kinase or Syk inhibitors)

Cannot have received: BCL-2 inhibitor (venetoclax)

prior exposure to ... a BCL-2 inhibitor (e.g. venetoclax)